Date: 03 May 2012
Targeted Therapy for Gastric Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
For patients with advanced gastric cancer, traditional double or triplet cytotoxic chemotherapy regimens result in a median survival of 9–11 months. As combination therapy is associated with increased survival, but also increased toxicity in a patient population whose performance status often compromised by their malignancy, development of more effective and less toxic treatment choices is mandated. Emerging data from gene expression profiling suggests that differences in pathological appearance and clinical behavior may be due the presence of unique molecular phenotypes. Characterization of the gastric cancer genomic landscape reveals the presence of multiple alterations in expression of receptor tyrosine kinases, which in conjunction with their ligands and downstream effector molecules represent potentially druggable pathways for future drug development. Treatment of HER2 positive gastric cancer with trastuzumab has led to significant gains in overall survival, and further manipulation of this pathway using the novel anti-HER2 directed agents pertuzumab and T-DM1 in addition to dual EGFR/HER2 blockade with lapatinib may yield positive results. In contrast, targeting of the EGFR pathway in combination with chemotherapy in unselected patients has not been fruitful to date, with no significant gains over standard chemotherapy yet demonstrated. Similarly, use of the anti-angiogenic monoclonal antibody bevacizumab was not successful in a large global randomized trial; however intriguing regional variations were seen with respect to efficacy of this drug, leading to calls for a second, regionally stratified study. Careful selection of patient subsets will become a key factor in future clinical trials, as novel targeted agents such as those targeting the MET/HGF and FGFR axes move forward into clinical development. It is hoped that treatment of patients in such molecularly defined groups is will lead to significant gains in survival compared to current treatment paradigms.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Wagner AD, Unverzagt S, GrotheW, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;(3): p. CD004064.
Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8(4):437–47.PubMed
Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012. Comprehensive review of genomic landscape of gastric cancer.
Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Annals of Oncology 2011.
Hecht J, Urba G, Koehler M, Ellis C. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. Proc GI ASCO 2008;43(abstr 43).
Pishvaian M, Sakaeva D, Hsieh RK. A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer. J Clin Oncol 2011;29(suppl 4; abstr 88).
Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of Oncology 2010.
Enzinger P, Burtness B, Hollis D, Niedzwiecki D, Ilson D. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28(15s):p. abstr 4006.
Richards DA, Kocs DM, Spira AI. Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study. J Clin Oncol 2011;29(suppl; abstr 4015).
Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol. 2010;21(11):2213–9.PubMedCrossRef
Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 2011;11:509.PubMedCrossRef
Pinto C, Mutri V, Di Fabi F. Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. J Clin Oncol 2010. 28(suppl; abstr 4133).
Enzinger P, Ryan D, Regan E. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. JCO 2008;26(4552):p. abstr 97.
Okines A, Langley R, Cafferty F, et al. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol 2010;28 (15 suppl:4019).
Ilson D, Janjigian Y, Shah M. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma. J Clin Oncol 2011;29(suppl 4; abstr 41).
Bang Y-J, Kang Y-K, Kang W, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs 2010; p. 1–10.
Van Cutsem E, Yeh K, Bang Y. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012;30(suppl 4; abstr LBA3).
Jhawer MKH, Wainberg Z, Ford F. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009;27(15s):p. (suppl; abstr 4502)
Iveson T, Donehower I, DAvidenco S. Safety and Efficacy of Epirubicin, Cisplatin and Capecitabine (ECX) plus rilotumumab as first line treatment for unresectable locally advanced or metastatic gastric or esophagogastric junction carcinoma, in ECCO 2011: Stockholm.
Gavine PR, Mooney L, Kilgour E, et al. AZD4547: An orally bioavailable, potent and selective inhibitor of the Fibroblast Growth Factor Receptor tyrosine kinase family. Cancer Research 2012.
Ratain M, Schwartz G, Orza A. Brivanib (BMS-582664) in advanced solid tumors (AST): results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011;29(suppl; abstr 3079).
Woll E, Greil R, Eisterer W, et al. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). Anticancer Res. 2011;31(12):4439–43.PubMed
- Targeted Therapy for Gastric Cancer
Current Treatment Options in Oncology
Volume 13, Issue 3 , pp 377-389
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Gastric cancer
- Targeted therapy
- Molecular classification
- Industry Sectors